Jackson H C, Nutt D J
Reckitt and Colman Psychopharmacology Unit, Department of Pharmacology, School of Medical Sciences, University Walk, Bristol, U.K.
Neuropharmacology. 1992 Nov;31(11):1081-7. doi: 10.1016/0028-3908(92)90002-7.
Idazoxan (10 mg/kg, i.p.) produces an unexpected increase in food intake in freely-feeding rats which has been linked to its high affinity for non-adrenoceptor idazoxan binding sites. In this study, a dose-related antagonism of idazoxan-induced food intake by the beta-adrenoceptor antagonist (-)-propranolol (5-20 mg/kg, i.p.), which also blocks 5-HT1 (5-hydroxytryptamine1) receptors has been demonstrated. (+)-Propranolol (10, 20 mg/kg, i.p.) did not attenuate idazoxan-induced feeding. (-)-Propranolol (10 mg/kg, i.p.) but not the (+)-enantiomer (10 mg/kg, i.p.) also significantly inhibited the food intake, induced by the 5-HT1A agonist 8-OH-DPAT (0.25 mg/kg, i.p.). Idazoxan-induced feeding was not altered by the selective beta-adrenoceptor antagonists betaxolol (beta 1; 5 mg/kg, i.p.) and ICI 118,551 (beta 2; 5 mg/kg, i.p.) but was potentiated by the 5-HT receptor antagonist metergoline (5 mg/kg, i.p.). The anomalous findings with metergoline may reflect its action at different sub-types of 5-HT receptor. The water intake induced by idazoxan and the peripherally-active alpha 2-adrenoceptor antagonist L-659,066 was also blocked in a stereoselective manner by propranolol (10 mg/kg) but not significantly by either metergoline (5 mg/kg, i.p.), the beta 1-adrenoceptor antagonist betaxolol (5 mg/kg, i.p.) nor by the beta 2-adrenoceptor antagonist ICI 118,551 (5 mg/kg, i.p.). These results suggest that the food intake induced by idazoxan (and perhaps mediated by non-adrenoceptor idazoxan binding sites) may involve the 5-HT system, although further studies, using antagonists acting selectively at the different sub-types of 5-HT receptor, are required to confirm this.(ABSTRACT TRUNCATED AT 250 WORDS)
咪唑克生(10毫克/千克,腹腔注射)可使自由进食的大鼠食量意外增加,这与它对非肾上腺素能咪唑克生结合位点的高亲和力有关。在本研究中,已证实β-肾上腺素能拮抗剂(-)-普萘洛尔(5 - 20毫克/千克,腹腔注射)对咪唑克生诱导的进食具有剂量相关的拮抗作用,该拮抗剂也能阻断5-HT1(5-羟色胺1)受体。(+)-普萘洛尔(10、20毫克/千克,腹腔注射)并未减弱咪唑克生诱导的进食。(-)-普萘洛尔(10毫克/千克,腹腔注射)而非(+)-对映体(10毫克/千克,腹腔注射)也显著抑制了由5-HT1A激动剂8-OH-DPAT(0.25毫克/千克,腹腔注射)诱导的进食。咪唑克生诱导的进食不受选择性β-肾上腺素能拮抗剂倍他洛尔(β1;5毫克/千克,腹腔注射)和ICI 118,551(β2;5毫克/千克,腹腔注射)的影响,但5-HT受体拮抗剂麦角新碱(5毫克/千克,腹腔注射)可增强其作用。麦角新碱的异常结果可能反映了其对不同亚型5-HT受体的作用。普萘洛尔(10毫克/千克)也以立体选择性方式阻断了咪唑克生和外周活性α2-肾上腺素能拮抗剂L-659,066诱导的饮水,但麦角新碱(5毫克/千克,腹腔注射)、β1-肾上腺素能拮抗剂倍他洛尔(5毫克/千克,腹腔注射)或β2-肾上腺素能拮抗剂ICI 118,551(5毫克/千克,腹腔注射)均未产生显著影响。这些结果表明,咪唑克生诱导的进食(可能由非肾上腺素能咪唑克生结合位点介导)可能涉及5-HT系统,不过需要使用对不同亚型5-HT受体具有选择性作用的拮抗剂进行进一步研究来证实这一点。(摘要截短至250字)